A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
NCT05694767
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
22
Enrollment
OTHER
Sponsor class
Conditions
Immune Thrombocytopenia
Treatment
Interventions
DRUG:
CM313 Injection
Sponsor
Institute of Hematology & Blood Diseases Hospital, China